Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/20825Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Roukos, D. H. | en |
| dc.contributor.author | Briasoulis, E. | en |
| dc.date.accessioned | 2015-11-24T19:10:24Z | - |
| dc.date.available | 2015-11-24T19:10:24Z | - |
| dc.identifier.issn | 1743-4262 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/20825 | - |
| dc.rights | Default Licence | - |
| dc.subject | Breast Neoplasms/*genetics/prevention & control/therapy | en |
| dc.subject | Female | en |
| dc.subject | Genes, BRCA1 | en |
| dc.subject | Genes, BRCA2 | en |
| dc.subject | Genetic Counseling | en |
| dc.subject | *Genetic Predisposition to Disease | en |
| dc.subject | Genetic Testing | en |
| dc.subject | Humans | en |
| dc.subject | Mastectomy | en |
| dc.subject | Neoplastic Syndromes, Hereditary/*prevention & control/therapy | en |
| dc.subject | Ovarian Neoplasms/*genetics/prevention & control/therapy | en |
| dc.subject | Ovariectomy | en |
| dc.subject | Tamoxifen/therapeutic use | en |
| dc.title | Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1038/ncponc0930 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/17898808 | - |
| heal.identifier.secondary | http://www.nature.com/nrclinonc/journal/v4/n10/pdf/ncponc0930.pdf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2007 | - |
| heal.abstract | Life-saving, risk-reducing medical interventions are required for women with a BRCA1/2 mutation. Interventions comprise a four-stage approach that involves risk assessment, genetic counseling, gene-mutation analysis and medical intervention strategies. Genetic counseling should be offered at specialized familial breast-cancer clinics and gene-mutation analysis should be recommended on the basis of personal and family-history-based risk criteria. Prophylactic bilateral salpingo-oophorectomy appears to offer the optimal benefit-risk ratio compared with prophylactic bilateral mastectomy, chemoprevention, or intensified surveillance. Tamoxifen is an alternative approach only for BRCA2 mutation carriers. The comprehensive, clinical decision-making Ioannina algorithm provided here can facilitate the complex preventive strategic approach. Newly diagnosed BRCA1/2 carriers might benefit from extensive surgery and a specific pharmacological treatment, but data to support this strategy are limited. Microarray gene-expression studies show that breast tumors from BRCA1 carriers are predominantly of basal subtype (i.e. triple negative) and BRCA2 carriers are of luminal subtype (i.e. estrogen-receptor-positive). Although optimum management of women with familial susceptibility to breast and ovarian cancer has not yet been prospectively validated, data indicate substantial benefits when an individualized evidence-based prevention strategy is provided by an experienced team. | en |
| heal.journalName | Nat Clin Pract Oncol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Roukos-2007-Individualized preve.pdf | 441.6 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
